Bioferon (interferon alpha 2b) / Biosidus - LARVOL DELTA

SWOG S1404: Physician/Patient Choice of Either High-Dose Recombinant Interferon Alfa-2B or Ipilimumab, Versus Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery (clinicaltrials.gov) - P3 | N=1378 | Not yet recruiting | Sponsor: National Cancer Institute (NCI)

New P3 trial • Breast Cancer • Cutaneous Melanoma • Melanoma • Mucosal Melanoma • Oncology • Solid Tumor • CD4

SWOG S1404: Physician/Patient Choice of Either High-Dose Recombinant Interferon Alfa-2B or Ipilimumab, Versus Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery (clinicaltrials.gov) - P3 | N=1345 | Active, not recruiting | Sponsor: National Cancer Institute (NCI)

Trial completion date • Breast Cancer • Cutaneous Melanoma • Melanoma • Mucosal Melanoma • Oncology • Solid Tumor • CD4

SWOG S1404: Physician/Patient Choice of Either High-Dose Recombinant Interferon Alfa-2B or Ipilimumab, Versus Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery (clinicaltrials.gov) - P3 | N=1301 | Active, not recruiting | Sponsor: National Cancer Institute (NCI) | Trial completion date: Jan 2025 ➔ Jan 2026

Trial completion date • Breast Cancer • Cutaneous Melanoma • Melanoma • Mucosal Melanoma • Oncology • Solid Tumor • CD4

SWOG S1404: Physician/Patient Choice of Either High-Dose Recombinant Interferon Alfa-2B or Ipilimumab, Versus Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery (clinicaltrials.gov) - P3 | N=1301 | Active, not recruiting | Sponsor: National Cancer Institute (NCI) | Trial completion date: Jan 2026 ➔ Jan 2027

Trial completion date • Breast Cancer • Cutaneous Melanoma • Melanoma • Mucosal Melanoma • Oncology • Solid Tumor • CD4

SWOG S1404: Physician/Patient Choice of Either High-Dose Recombinant Interferon Alfa-2B or Ipilimumab, Versus Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery (clinicaltrials.gov) - P3 | N=1378 | Active, not recruiting | Sponsor: National Cancer Institute (NCI) | Trial primary completion date: Jun 2020 ➔ Sep 2023

Trial primary completion date • Breast Cancer • Cutaneous Melanoma • Melanoma • Mucosal Melanoma • CD4

SWOG S1404: Physician/Patient Choice of Either High-Dose Recombinant Interferon Alfa-2B or Ipilimumab, Versus Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery (clinicaltrials.gov) - P3 | N=1378 | Recruiting | Sponsor: National Cancer Institute (NCI) | Not yet recruiting ➔ Recruiting

Breast Cancer • Cutaneous Melanoma • Melanoma • Mucosal Melanoma • Oncology • Solid Tumor • CD4

SWOG S1404: Physician/Patient Choice of Either High-Dose Recombinant Interferon Alfa-2B or Ipilimumab, Versus Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery (clinicaltrials.gov) - P3 | N=1378 | Active, not recruiting | Sponsor: National Cancer Institute (NCI) | Recruiting ➔ Active, not recruiting

Enrollment closed • Breast Cancer • Cutaneous Melanoma • Melanoma • Mucosal Melanoma • CD4

SWOG-S0518: Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor (clinicaltrials.gov) - P3 | N=427 | Active, not recruiting | Sponsor: National Cancer Institute (NCI) | Trial completion date: Jan 2026 ➔ Jan 2027

Trial completion date • Endocrine Cancer • Gastric Cancer • Gastrointestinal Neuroendocrine Tumor • Neuroendocrine Tumor • Oncology • Solid Tumor • Thyroid Gland Carcinoma

Rintatolimod, Celecoxib and Interferon Alpha 2b With Pembrolizumab For the Treatment of Patients With Metastatic or Unresectable Triple Negative Breast Cancer (clinicaltrials.gov) - P1/2 | N=5 | Terminated | Sponsor: Roswell Park Cancer Institute | Trial completion date: Dec 2025 ➔ Jun 2025 | Active, not recruiting ➔ Terminated; Funding ended

Trial completion date • Trial termination • Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer

Rintatolimod, Celecoxib and Interferon Alpha 2b With Pembrolizumab For the Treatment of Patients With Metastatic or Unresectable Triple Negative Breast Cancer (clinicaltrials.gov) - P1/2 | N=5 | Active, not recruiting | Sponsor: Roswell Park Cancer Institute | Recruiting ➔ Active, not recruiting | N=15 ➔ 5 | Trial completion date: Jun 2025 ➔ Dec 2025

Enrollment change • Enrollment closed • Trial completion date • Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer

Rintatolimod, Celecoxib and Interferon Alpha 2b With Pembrolizumab For the Treatment of Patients With Metastatic or Unresectable Triple Negative Breast Cancer (clinicaltrials.gov) - P1/2 | N=12 | Recruiting | Sponsor: Roswell Park Cancer Institute | Trial completion date: Dec 2025 ➔ Jun 2025 | Trial primary completion date: Dec 2025 ➔ Jun 2025

Metastases • Trial completion date • Trial primary completion date • Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer

Rintatolimod, Celecoxib and Interferon Alpha 2b With Pembrolizumab For the Treatment of Patients With Metastatic or Unresectable Triple Negative Breast Cancer (clinicaltrials.gov) - P1/2 | N=12 | Recruiting | Sponsor: Roswell Park Cancer Institute | Not yet recruiting ➔ Recruiting

Enrollment open • Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer

Rintatolimod, Celecoxib and Interferon Alpha 2b With Pembrolizumab For the Treatment of Patients With Metastatic or Unresectable Triple Negative Breast Cancer (clinicaltrials.gov) - P1/2 | N=12 | Not yet recruiting | Sponsor: Roswell Park Cancer Institute | Trial completion date: Jun 2025 ➔ Dec 2025 | Initiation date: Sep 2023 ➔ Dec 2023 | Trial primary completion date: Jun 2025 ➔ Dec 2025

Metastases • Trial completion date • Trial initiation date • Trial primary completion date • Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer

Rintatolimod, Celecoxib and Interferon Alpha 2b With Pembrolizumab For the Treatment of Patients With Metastatic or Unresectable Triple Negative Breast Cancer (clinicaltrials.gov) - P1/2 | N=12 | Not yet recruiting | Sponsor: Roswell Park Cancer Institute | Trial completion date: Jul 2027 ➔ Jun 2025 | Trial primary completion date: Jul 2026 ➔ Jun 2025

Metastases • Trial completion date • Trial primary completion date • Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer

Rintatolimod, Celecoxib and Interferon Alpha 2b With Pembrolizumab For the Treatment of Patients With Metastatic or Unresectable Triple Negative Breast Cancer (clinicaltrials.gov) - P1/2 | N=12 | Not yet recruiting | Sponsor: Roswell Park Cancer Institute | Trial completion date: Apr 2027 ➔ Jul 2027 | Trial primary completion date: Apr 2026 ➔ Jul 2026

Metastases • Trial completion date • Trial primary completion date • Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer

Rintatolimod, Celecoxib and Interferon Alpha 2b With Pembrolizumab For the Treatment of Patients With Metastatic or Unresectable Triple Negative Breast Cancer (clinicaltrials.gov) - P1/2 | N=12 | Not yet recruiting | Sponsor: Roswell Park Cancer Institute

Metastases • New P1/2 trial • Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer